Darius Lakdawalla is a leading authority on pharmaceutical economics. Professor Lakdawalla focuses on topics related to health economics and health policy, including the value and determinants of medical innovation, the economics of health insurance and risks to health, and the industrial organization of healthcare markets. He has particular expertise with issues involving pharmaceutical industry policy, prescription drug insurance coverage and reimbursement, and alternative payment models for pharmaceuticals.
Professor Lakdawalla has served as a consulting expert in life sciences and healthcare litigation in both state and federal courts, where he addressed liability and damages issues. He has quantified the impact of pharmaceutical marketing on drug sales, analyzed irreparable harm due to patent infringement, and estimated damages related to Medicare Part D reimbursement and optimal use of medical services. Professor Lakdawalla also has years of experience providing business consulting services to major pharmaceutical companies.
An award-winning researcher, Professor Lakdawalla has published articles in leading economics, medical, and health policy journals, including the American Economic Review, Health Affairs, and the Journal of the American Medical Association. His article “Economics of the Pharmaceutical Industry” was published in the Journal of Economic Literature. He has also coauthored chapters in the Handbook of Health Economics, The Oxford Handbook of the Economics of the Biopharmaceutical Industry, and The Elgar Companion to Health Economics (2nd edition), among others.
In addition to serving on several editorial boards, Professor Lakdawalla is associate editor for the American Journal of Health Economics and the Journal of Health Economics. He previously served as associate editor for the Review of Economics and Statistics, and as an expert panelist for the National Academy of Medicine. Professor Lakdawalla is a research associate at the National Bureau of Economic Research (NBER).
For more than a decade, Professor Lakdawalla has taught courses on health economics and policy, as well as health management. Prior to joining USC, he served as senior economist and director of research at the RAND Corporation’s Bing Center for Health Economics.
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
COVID-19 Implications for Pharmaceutical Litigation